Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 4.20M | 3.92M | 6.22M | 26.91M | 103.87M | 103.18M |
Gross Profit | -91.00K | -342.00K | 106.00K | 20.57M | 45.49M | 47.66M |
EBITDA | -154.85M | -123.50M | -89.23M | -66.00M | -84.07M | -70.41M |
Net Income | -156.65M | -126.23M | -95.90M | -79.78M | -96.77M | -103.77M |
Balance Sheet | ||||||
Total Assets | 128.79M | 145.27M | 151.04M | 215.98M | 359.86M | 314.59M |
Cash, Cash Equivalents and Short-Term Investments | 80.24M | 97.91M | 62.85M | 55.95M | 115.16M | 100.12M |
Total Debt | 5.42M | 5.50M | 7.10M | 51.42M | 194.20M | 182.28M |
Total Liabilities | 142.85M | 106.75M | 32.55M | 89.72M | 252.51M | 247.41M |
Stockholders Equity | -14.06M | 38.51M | 118.50M | 126.26M | 107.35M | 67.17M |
Cash Flow | ||||||
Free Cash Flow | -75.26M | -76.76M | -68.47M | -69.97M | -63.02M | -84.55M |
Operating Cash Flow | -70.41M | -68.17M | -66.93M | -65.05M | -55.77M | -77.02M |
Investing Cash Flow | -51.22M | -20.71M | -3.09M | 226.42M | -74.54M | 27.78M |
Financing Cash Flow | 109.90M | 110.58M | 29.59M | -155.29M | 121.19M | 32.70M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | $520.77M | ― | -216.14% | ― | 203.23% | -80.71% | |
54 Neutral | $603.49M | ― | -45.46% | ― | -78.26% | 15.41% | |
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% | |
51 Neutral | $428.01M | ― | -278.55% | ― | -22.76% | -46.69% | |
41 Neutral | $516.89M | ― | -27.04% | ― | ― | 6.72% | |
40 Neutral | $504.70M | ― | -37.07% | ― | ― | 26.24% | |
33 Underperform | $658.62M | ― | -71.44% | ― | ― | 19.94% |
At the Annual Meeting of Stockholders on June 26, 2025, Precigen, Inc. announced several key approvals, including an amendment to increase the shares available under its 2023 Omnibus Incentive Plan by 11.5 million. Additionally, stockholders approved increasing the company’s authorized shares of common stock by 300 million and ratified Deloitte & Touche LLP as the independent accounting firm for 2025. These decisions are expected to impact Precigen’s operational flexibility and shareholder value positively.
The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.